Ainos SARS-CoV-2 Antigen Rapid Test Kit

About Ainos

Ainos is executing a strategic transformation from a legacy interferon developer into a diversified medtech company centered on AI-driven diagnostics. Its core achievement is the development of a proprietary 'AI Nose' platform, which uses MEMS sensor arrays and AI algorithms to analyze volatile organic compounds (VOCs) for non-invasive, point-of-care testing, with initial commercial products for COVID-19 and pneumonia. The strategy leverages nearly four decades of clinical experience and over 60 patents across three divisions: Pharmaceuticals (low-dose interferon), Medical Devices (AI diagnostics), and Preventive Medicine (synthetic RNA), aiming to address unmet needs in infectious disease, women's health, and chronic conditions.

Therapeutic Areas

Other COVID-19 Diagnosis Drugs